Results 211 to 220 of about 12,905,954 (250)
Some of the next articles are maybe not open access.
Expanded spectrum of recombinant human growth hormone therapy
Current Opinion in Pediatrics, 2002The efficacy of recombinant human growth hormone in the treatment of growth hormone deficiency is well established. In recent years, the use of recombinant human growth hormone as a therapeutic modality has greatly increased and has expanded beyond the realm of replacement for growth hormone deficiency.
Maria J, Henwood +2 more
openaire +2 more sources
Safety of High Doses of Recombinant Human Growth Hormone
Hormone Research in Paediatrics, 1998Recombinant human growth hormone (r-hGH) is given as substitution therapy to growth hormone-deficient children at 0.01–0.025 mg/kg/day. Higher doses are used for short stature due to Turner’s syndrome and for idiopathic short stature (approximately 0.05 mg/kg/day).
openaire +3 more sources
Supercritical Fluids Processing of Recombinant Human Growth Hormone
Drug Development and Industrial Pharmacy, 2005The aim of the study was to investigate the feasibility of precipitating recombinant human growth hormone (hGH) from aqueous solutions using conventional and modified techniques of solution-enhanced dispersion (SEDS) by supercritical fluids. The study investigated the effect on hGH stability of adding isopropanol either as a cosolvent with the original
Sitaram P, Velega, Johan, Carlfors
openaire +2 more sources
Use of Recombinant Human Growth Hormone in Children with Thalassemia
Hormone Research in Paediatrics, 2009<i>Background:</i> Growth failure occurs in children with chronic anemias and, in particular, in approximately 30% of those with thalassemia. <i>Methods:</i> We assessed recombinant human growth hormone (rhGH) use in a large cohort of children with thalassemia enrolled in the Pfizer International Growth Study Database (KIGS ...
Mitchell E, Geffner, Hanna, Karlsson
openaire +2 more sources
Recombinant Human Growth Hormone
BioDrugs, 2008The role of hormonal and metabolic alterations in HIV-associated lipodystrophy syndrome is not yet clear. In patients with HIV-1 undergoing antiretroviral treatment, lipodystrophy is associated with peripheral fat wasting and central adiposity, dyslipidemia, insulin resistance, and increased intramuscular fat accumulation. In HIV lipodystrophy, changes
S. Benedini +3 more
openaire +3 more sources
Crystallization of Authentic Recombinant Human Growth Hormone
Nature Biotechnology, 1987Large single crystals of natural–sequence recombinant human growth hormone (r–hGH) have been grown from a medium containing polyethylene glycol and a non–ionic detergent, β–octyl glucoside. The identity of the crystals was confirmed by gel electrophoresis and anion exchange chromatography.
Noel D. Jones +3 more
openaire +1 more source
Clinical Experience with Authentic Recombinant Human Growth Hormone
Acta Paediatrica, 1986ABSTRACT. Studies of authentic recombinant human growth hormone (rhGH) began very recently in Germany. In this study, one group of patients with hGH deficiency is naïve (no previous hGH treatment), and the second group has been treated with pituitary hGH.
openaire +2 more sources
Management of Recombinant Human Growth Hormone Therapy at Puberty
Hormone Research in Paediatrics, 1998Treatment modalities for growth hormone (GH) substitution in GH-deficient children at puberty is still a matter of debate. Although circulating GH levels increase during puberty, it has not been proven that the increase of exogenous GH is necessary for a normal pubertal growth spurt.
openaire +2 more sources
Recombinant DNA Synthesis of Human Growth Hormone
1986Human growth hormone (hGH) is a polypeptide of approximately 22,000 daltons in size that is synthesized in the pituitary. Mature hGH has been produced in Escherichia coli bacteria using recombinant DNA technology(1) using the scheme outlined in Fig. 1. The process involved cloning of cDNA to the pituitary hGH mRNA(2) and the subsequent adapting of the ...
Michael J. Ross +4 more
openaire +1 more source
Pediatric Nephrology, 1996
Many of the metabolic actions of growth hormone (GH) are mediated through insulin-like growth factors or somatomedins. Recombinant human insulin-like growth factor-I (rhIGF-I) has a dichotomous insulin-like and GH-like action when used in different clinical situations in humans.
N, Mauras, M W, Haymond
openaire +2 more sources
Many of the metabolic actions of growth hormone (GH) are mediated through insulin-like growth factors or somatomedins. Recombinant human insulin-like growth factor-I (rhIGF-I) has a dichotomous insulin-like and GH-like action when used in different clinical situations in humans.
N, Mauras, M W, Haymond
openaire +2 more sources